



<b>Personal Information</b>	Sex: M	Date Drawn: 12/30/2007
Patient name: John Doe	Age: 43	Date Tested: 12/31/2007
Account: Internal Medicine	DOB: 06/04/1964	Accession: 12345678
Physician: James Doe	Client No: 38176	Patient ID: 30819

Direct-Measured Cholesterol Panel	Actual	Desirable	Risk		Description
			Low	High	
<b>Total LDL</b>	<b>89</b>	<130 mg/dL	▼		LDL-R + Lp(a) + IDL
LDL-R (Real LDL)	72	<100 mg/dL	▼		Total LDL minus Lp(a) and IDL
Lp(a)	2	<10 mg/dL	▼		More atherogenic than LDL
IDL	15	<20 mg/dL	▼		More atherogenic than LDL
<b>Total HDL</b>	<b>43</b>	≥40 mg/dL	▼		HDL <sub>2</sub> + HDL <sub>3</sub>
HDL <sub>2</sub>	6	>10 mg/dL		▼	Large Buoyant, more protective
HDL <sub>3</sub>	37	>30 mg/dL	▼		Small Dense, less protective
<b>Total VLDL</b>	<b>29</b>	<30 mg/dL	▼		VLDL <sub>1+2</sub> + VLDL <sub>3</sub>
VLDL <sub>1+2</sub>	14	<20 mg/dL	▼		Buoyant VLDL, less risk
VLDL <sub>3</sub>	15	<10 mg/dL		▼	Dense VLDL, more risk
<b>Total Cholesterol</b>	<b>161</b>	<200 mg/dL	▼		LDL + HDL + VLDL

\*Elevated triglycerides (TG) may affect apoB<sub>100</sub> (TG>499) or other lipid values (TG>1000).

Secondary and Emerging Risk Factors	Actual	Desirable	Risk		Description
			Low	High	
Triglycerides	200	<150 mg/dL		▼	Linked to increased risk for CHD
Non-HDL Cholesterol	118	<160 mg/dL	▼		LDL + VLDL
Remnant Lipoproteins	30	<30 mg/dL		▼	IDL + VLDL <sub>3</sub>
Lp(a)	2	<10 mg/dL	▼		More atherogenic than LDL
LDL Density (Pattern)	B	Pattern A		▼	B: more risk; A/B intermediate risk; A: less risk
LDL Subclasses (mg/dL) LDL <sub>4</sub> =10, LDL <sub>3</sub> =45, LDL <sub>2</sub> =15, LDL <sub>1</sub> =5					LDL <sub>4+3</sub> small, dense. LDL <sub>2+1</sub> large, buoyant

VAP Derived Apolipoproteins	Actual	Desirable	Risk		Description
			Low	High	
Apo B <sub>100</sub>	91	< 109 mg/dL	▼		Sum atherogenic lipoprotein particles
Apo A1	116	> 118 mg/dL	▼		Sum anti-atherogenic lipoprotein particles
Apo B <sub>100</sub> /A1 ratio	0.00	<0.00		▼	Low ratio indicates lower risk

Metabolic Syndrome/Insulin Resistant Assessment	Considerations
<p><b>Atherogenic Dyslipidemia</b></p> <p><input checked="" type="checkbox"/> Triglycerides ≥150 mg/dL</p> <p><input checked="" type="checkbox"/> HDL<sub>2</sub> &lt;10mg/dL males &lt;15mg/dL females</p> <p><input checked="" type="checkbox"/> Pattern B</p> <p><b>Physician Input Required</b></p> <p><input type="checkbox"/> Systolic BP ≥130/≥85 mm Hg</p> <p><input type="checkbox"/> Fasting Glucose ≥110 mg/dL</p> <p><input type="checkbox"/> Abdominal Obesity &gt;102 cm (&gt;40 in) &gt;88 cm (&gt;35 in)</p>	<p>The normal LDL target of &lt;130mg/dL* for moderate risk patients can be lowered to &lt;100mg/dL* due to the presence of any of the following ATP III emerging risks factors:</p> <p><input checked="" type="checkbox"/> <b>LDL Size — Dense (Pattern B)</b></p> <p><input checked="" type="checkbox"/> <b>Remnant Lipoproteins elevated</b></p> <p><input type="checkbox"/> <b>Lp(a)</b></p> <p>* If patient is defined as very high risk LDL target of &lt;70 mg/dL can be considered.</p>

Note: Atherotech does not attempt to mandate or advise treatment for individual patients. The considerations are to be used along with clinical judgment and risk assessment. Final recommendations lie with the clinician.